**66th ASH Annual Meeting 2024** (San Diego, USA) **–**
**Overview of CML related sessions**

Timings in Pacific Time (PT)

| Time slots | Sessions |
|---|---|
| **Satellite Symposia** | |
| Dec 6 (Friday)<br><br>7:00 – 10:00 a.m.<br><br>Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego) | **Satellite Symposium**: Addressing current questions and controversies in the management of chronic myeloid leukemia - What clinicians want to know<br><br>This program is supported by an educational grant from Novartis.<br><br>Chair: Michael J. Mauro<br>(Memorial Sloan Kettering Cancer Center New York, USA)<br><br>Speakers:<br>• Andreas Hochhaus (Jena, Germany)<br>• Douglas Smith (Baltimore, USA)<br><br>Program:<br><br>Prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of CML. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. |
| **Industry Theatres** (for in-person participants only) | |
| Dec 8 (Sunday)<br>8.00 – 9.00 a.m.<br>Room 1A (San Diego Convention Center) | **Industry Theatre**: The potential impact of 24-hour NGS results on myeloid and lymphoid malignancy sample characterization and research |
| Dec 8 (Sunday)<br>11.30 a.m. – 12.30 p.m.<br>Room 3 (San Diego | **Industry Theatre**: Addressing critical unmet needs with newly diagnosed Ph+ CML-CP |

| Time slots | Sessions |
|---|---|
| Convention Center) | |
| **Education Program** | |
| Dec 7 (Saturday)<br>9.30 – 10.45 a.m.<br>Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina) | **Education Session**: A little less conversation, a little more action: An outcome equity roadmap for children and AYAs with leukemia and lymphoma<br>Chair: Maria Monica Gramatges (Texas Children's Hospital, Houston, TX)<br>Program:<br>• The Lasting Impact of the ACA: How Medicaid Expansion Reduces Outcome Disparities in AYAs With Leukemia and Lymphoma (Xu Ji, Atlanta, USA)<br>• Targeting Hardship: Poverty as a Modifiable Risk Factor in Childhood Leukemia and Lymphoma Treatment (Puja J. Umaretiya, Dallas, USA)<br>• Sharing is Caring: A Network Collaborative Approach to Identify and Address Barriers in Accessing Clinical Trials in AYAs with Leukemia and Lymphoma (Nupur Mittal Nupur Mittal, Chicago, USA) |
| **Oral Abstract Sessions** | |
| Dec 8 (Sunday)<br>9:30 – 11.00 a.m.<br>Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego) | **Oral Session:** Chronic Myeloid Leukemia<br>Novel molecules in clinical practice<br>Moderators:<br>• Dragana Milojkovic (Imperial College Healthcare NHS Trust, London, UK)<br>• Nobuko Hijiya (Columbia University Medical Center, New York, UK)<br>Program:<br>• 9.30 a.m.: Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study (Cortes JE et al.) (475)<br>• 9.45 a.m.: Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare (Yeung DT et al. (476)<br>• 10.00 a.m.: Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001 (Jiang Q et al.) |

| Time slots | Sessions |
|---|---|
| | (477)<br>• 10.15 a.m.: 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting (Nicolini FE et al.) (478)<br>• 10.30 a.m.: Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) (Atallah EL et al.) (479)<br>• 10.45 a.m.: Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) (Weiming L et al.) (480) |
| Dec 8 (Sunday)<br>9:30 - 11:00 a.m.<br>Grand Hall B (Manchester Grand Hyatt San Diego) | **Oral Session**: Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity<br>CML Presentations:<br>• 10.30 a.m.: Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP) (Beaudet ME et al.) (533)<br>• 10.45 a.m.: Chronic Myeloid Leukemia: Impact of Social and Demographic Disparities on Survival Outcomes (Mukhtiar VP et al.) (534) |
| Dec 9 (Monday)<br>4:30 – 6.00 p.m.<br>Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego) | **Oral Session:** Chronic Myeloid Leukemia<br>Clinical and epidemiological: Alternative laboratory predictors of outcome<br>Moderators:<br>• Thomas Ernst (Jena University Hospital, Germany)<br>• Sarit E. Assouline (Jewish General Hospital, Quebec, Canada)<br>Program:<br>• 4.30 p.m.: Strong Association between Cancer Gene Variants at Diagnosis, Especially *ASXL1*, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors (Shanmunagathan N et al.) (991)<br>• 4.45 p.m.: Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The Other from the Gimema Labnet Network (Stagno F et al.) (992)<br>• 5.00 p.m.: Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia (Ross DM et al) (993)<br>• 5.15 p.m.: Common Lymphoid Progenitors and B Cell Subpopulations in the Bone Marrow Are Predictive of Treatment-Free Remission in |

| Time slots | Sessions |
|---|---|
| | Chronic Myeloid Leukemia (Patterson SD et al) (994)<br>• 5.30 p.m.: FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study (Sicuranza A et al.) (995)<br>• 5.45 p.m.: Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure (Branford S et al.) (996) |
| **Poster Presentations** (for in-person participants) | |
| Dec 7 (Saturday)<br>5:30 – 7.30 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session:** Chronic Myeloid Leukemia Clinical and Epidemiological: Poster I<br>Poster:<br>• 1765: Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial (Cortes JE et al.)<br>• 1766: Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - An Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group) (Isfort S et al.)<br>• 1767: Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China (Yuan M et al.)<br>• 1768: Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients (Chiu M et al.)<br>• 1769: A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study (Huang J et al.)<br>• 1770: A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study (Huang J et al.)<br>• 1771: Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch (Rebechi MT et al)<br>• 1772: Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 - 60 Years: A CML Study (Latagliata R et al.) |

| Time slots | Sessions |
|---|---|
| | • 1773: Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML (Xu N et al.)<br>• 1774: The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients (Ernst T et al.)<br>• 1775: Tyrosine Kinase Inhibitors Short Exposure in Pregnant Female Patients with Chronic Myeloid Leukemia (Zu Y et al.)<br>• 1776: Vitamin D Deficiency Negatively Affects Responses in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors (Chuengviroj V et al.)<br>• 1777: Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study (Zureigat H et al.)<br>• 1778: Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy (Grano S et al.)<br>• 1779: A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (Lee S et al.)<br>• 1780: Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML (Purhonen M et al.) |
| Dec 7 (Saturday),<br>5:30 - 7:30 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session:**<br>Outcome research: Myeloid malignancies Poster I<br>CML Poster:<br>• 2426: Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium (Jain AG et al.)<br>• 2427: Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI) (Breccia M et al)<br>• 2434: Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States (Jabbour E et al.) |

| Time slots | Sessions |
|---|---|
| Dec 8 (Sunday)<br>6:00 – 8.00 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session:** Chronic Myeloid Leukemia<br>Clinical and Epidemiological: Poster II<br>Poster<br>• 3148: 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results (Cortes JE et al.)<br>• 3149: Retrospective Study to Compare Treatment Outcomes of Asciminib Vs. Ponatinib in 99 Patients with T315I Mutated Chronic Myeloid Leukemia (Perusini MA et al.)<br>• 3150: Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study (Rousselot P et al.)<br>• 3151: Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses (Jabbour E et al.)<br>• 3152: Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations (Rockwell B et al.)<br>• 3153: Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia (Jain AG et al.)<br>• 3154: Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study (Halder R et al.)<br>• 3155: CML Patients Who Fail to Achieve 1% BCR::ABL1 at 12 Months or 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study (Giai V et al.)<br>• 3156: A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse (Karrar O et al.)<br>• 3157: Impact of the 2022 Who Classification on Chronic Myeloid Leukemia (Pagnano KB et al.)<br>• 3158: ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial (Soverini S et al.) |

| Time slots | Sessions |
|---|---|
| | • 3159: Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML (Stuckey R et al.)<br>• 3160: Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes (Miranda M et al.)<br>• 3161: Making Treatment Free Remission feasible in Low- and Middle-Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India (Jindal N et al.)<br>• 3162: Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy (Bonuomo V et al.)<br>• 3163: BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia (Innes AJ et al.) |
| Dec 8 (Sunday),<br>6:00 - 8:00 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session:** Health Services and Quality Improvement: Myeloid Malignancies: Poster II<br>CML Poster:<br>• 3677: Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers (Vaughn JE et al.) |
| Dec 8 (Sunday),<br>6:00 - 8:00 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session**: Outcomes Research: Myeloid Malignancies: Poster II<br>CML poster:<br>• 3810: Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience (Perusini MA et al.)<br>• 3812: Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) a Chart Review Study in the United States (Jadhav K et al.)<br>• 3816: Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience (Jabbour E et al.) |

| Time slots | Sessions |
|---|---|
| Dec 9 (Monday)<br>6:00 – 8.00 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session:** Chronic Myeloid Leukemia<br>Clinical and Epidemiological: Poster III<br>Posters:<br>• 4526: Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study (Hochhaus A et al.)<br>• 4527: ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs (Khanna A et al.)<br>• 4528: Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China (Bao M et al.)<br>• 4529: Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis (Zhang X et al.)<br>• 4530: Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study (Piciocchi A et al.)<br>• 4531: High-Risk Failure Events Predicting Worse Survival in Patients with Chronic Myeloid Leukemia during Tyrosine Kinase Inhibitor Therapy (Zhang X et al.)<br>• 4532: Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study (Abruzzese E et al.)<br>• 4533: Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib (Liu B et al.)<br>• 4534: Validation of Imatinib-Therapy Failure (IMTF) Score in Children with Chronic Myeloid Leukemia in the Chronic Phase (Jiang Q et al.)<br>• 4535: Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network (Breccia M et al.)<br>• 4536: Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study (Alzaidy N et al.) |

| Time slots | Sessions |
|---|---|
| | • 4537: Growth Retardation and Adult Height in Children with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors (Shima H et al.)<br>• 4538: Analysis of Arterial Occlusive Events (AOE) in CML Patients Using Real-World Data: A Large Cohort (Takaku T et al.)<br>• 4539: Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT) (Shukhov O et al.)<br>• 4540: Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (Weiming L et al.)<br>• 4541: A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy (Nardi V et al.) |
| Dec 9 (Monday),<br>6:00 - 8:00 p.m.<br>Halls G-H (San Diego Convention Center) | **Poster Session**: Outcomes Research: Myeloid Malignancies: Poster III<br>CML posters:<br>• 5185: Living with CML: A Qualitative Analysis (Schoenbeck K et al.)<br>• 5192: Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis (Vadnerkar G et al.) |